|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM304916587 |
| 003 |
DE-627 |
| 005 |
20231225120022.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2020 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2019.108329
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1016.xml
|
| 035 |
|
|
|a (DE-627)NLM304916587
|
| 035 |
|
|
|a (NLM)31891764
|
| 035 |
|
|
|a (PII)S1521-6616(19)30643-6
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a López-Oliva, Maria O
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Pre-transplant assessment of pp65-specific CD4 T cell responses identifies CMV-seropositive patients treated with rATG at risk of late onset infection
|
| 264 |
|
1 |
|c 2020
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 04.08.2020
|
| 500 |
|
|
|a Date Revised 04.08.2020
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2020 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Assessment of CMV-specific T cell immunity might be a useful tool in predicting CMV infection after solid organ transplantation. We have investigated CD4 and CD8 T-cell responses to CMV pp65 and IE-1 antigens in a prospective study of 28 CMV-seropositive kidney transplant recipients who were administered lymphocyte-depleting antibodies (Thymoglobulin®) as induction treatment and with universal prophylaxis for CMV infection. The response was analyzed by intracellular flow cytometry analysis of IFN-γ production in pretransplant samples and at 1, 6, 12 and 24 months post-transplant. Overall, only pretransplant CD4 T-cell responses to pp65 were significantly lower (p = .004) in patients with CMV replication post-transplant. ROC curve analysis showed that pre-transplant frequencies of pp65-specific CD4 + T cells below 0.10% could predict CMV infection with 75% sensitivity and 83.33% specificity (AUC: 0.847; 95% CI: 0.693-1.001; p = .0054) and seem to be mandatory for efficient control of CMV viral replication by the host immune system. In conclusion, the functional assessment of CMV-specific CD4 T-cell immunity pretransplant in seropositive patients may allow the identification of Thymoglobulin®-treated kidney transplant recipients at risk of developing CMV infection post-transplantation
|
| 650 |
|
4 |
|a Clinical Trial
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Adaptive immune response
|
| 650 |
|
4 |
|a Cytokine flow cytometry
|
| 650 |
|
4 |
|a Cytomegalovirus
|
| 650 |
|
4 |
|a Immune monitoring
|
| 650 |
|
4 |
|a Kidney transplant
|
| 650 |
|
7 |
|a Antilymphocyte Serum
|2 NLM
|
| 650 |
|
7 |
|a Antiviral Agents
|2 NLM
|
| 650 |
|
7 |
|a Immunosuppressive Agents
|2 NLM
|
| 650 |
|
7 |
|a thymoglobulin
|2 NLM
|
| 650 |
|
7 |
|a D7RD81HE4W
|2 NLM
|
| 650 |
|
7 |
|a Valganciclovir
|2 NLM
|
| 650 |
|
7 |
|a GCU97FKN3R
|2 NLM
|
| 700 |
1 |
|
|a Martínez, Virginia
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Rodríguez-Sanz, Aranzazu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Álvarez, Laura
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Santana, M José
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Selgas, Rafael
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jiménez, Carlos
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bellón, Teresa
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 211(2020) vom: 15. Feb., Seite 108329
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:211
|g year:2020
|g day:15
|g month:02
|g pages:108329
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2019.108329
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 211
|j 2020
|b 15
|c 02
|h 108329
|